Thromboembolic Risk in Prostate Cancer Patients Treated with PARP Inhibitors: A Systematic Review and Meta-analysis.
Clinical Trials
PARPi
Prostate Cancer
Thrombosis
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
27 Apr 2024
27 Apr 2024
Historique:
received:
04
02
2024
revised:
16
04
2024
accepted:
25
04
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
30
4
2024
Statut:
aheadofprint
Résumé
Poly (ADP-ribose) polymerase inhibitors (PARPi) have been associated with thrombotic events, although the association with thrombosis risk in different cancers remains poorly defined. This meta-analysis included phase II and phase III clinical trials in which patients with metastatic prostate cancer were treated with PARPi either as monotherapy or in combination. The primary endpoints were the rates of thromboembolic events in prostate cancer patients. A total of 2210 and 1662 patients with prostate cancer were compared in the PARP inhibitor and control groups, respectively. 96 (4.3%) and 37 (2.2%) patients had thrombosis in the PARPi and control groups, respectively. PARPi had a statistically significant increased risk of thrombosis in prostate cancer patients (Odds Ratio (OR)=1.98, 95% CI: 1.06-3.70, P=0.030). The heightened thrombotic risk associated with PARPi treatment in prostate cancer emphasizes the need for comprehensive management protocols to effectively reduce the risk and ensure safer outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Poly (ADP-ribose) polymerase inhibitors (PARPi) have been associated with thrombotic events, although the association with thrombosis risk in different cancers remains poorly defined.
METHODS
METHODS
This meta-analysis included phase II and phase III clinical trials in which patients with metastatic prostate cancer were treated with PARPi either as monotherapy or in combination. The primary endpoints were the rates of thromboembolic events in prostate cancer patients.
RESULTS
RESULTS
A total of 2210 and 1662 patients with prostate cancer were compared in the PARP inhibitor and control groups, respectively. 96 (4.3%) and 37 (2.2%) patients had thrombosis in the PARPi and control groups, respectively. PARPi had a statistically significant increased risk of thrombosis in prostate cancer patients (Odds Ratio (OR)=1.98, 95% CI: 1.06-3.70, P=0.030).
CONCLUSION
CONCLUSIONS
The heightened thrombotic risk associated with PARPi treatment in prostate cancer emphasizes the need for comprehensive management protocols to effectively reduce the risk and ensure safer outcomes.
Identifiants
pubmed: 38685459
pii: S1040-8428(24)00119-7
doi: 10.1016/j.critrevonc.2024.104376
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
104376Informations de copyright
Copyright © 2024. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest S.C.Y., E.A., and E.Y. declare no conflicts of interest to report. Y.U. declares research funding (Institutional and personal) from Turkish Oncology Group. Yüksel Ürün has served on the advisory board for Abdi-Ibrahim, Astellas, AstraZeneca, Bristol Myers-Squibb, Eczacıbası, Gilead, Janssen, Merck, Novartis, Pfizer, Roche. Y.U. received honoraria or has served as a consultant for Abdi-Ibrahim, Astellas, Bristol Myers-Squibb, Eczacıbası, Janssen, Merck, Novartis, Pfizer, Roche.